Risk of Secondary Acute Leukemia and Preleukemia After Hodgkin’s Disease: The Institut Gustave-Roussy Experience

摘要: Secondary acute nonlymphocytic leukemia (ANLL) and preleukemia have long been claimed to be one of the major long-term side effects treatment Hodgkin’s disease (HD) with intensive including alkylating agents radiotherapy (Baccarani et al. 1980; Canellos 1975; Castro 1983; Coleman 1982; Coltman Dixon Tester 1984) associated an increased risk ANLL (Bergsagel Blayney 1987; Boivin Hutchison 1981; Collaborative Study 1984; Dorreen 1986; Glicksman Larsen Brinker 1977; Pedersen-Bjergaard Tolland 1978; Tucker 1987a). Among various chemotherapy regimens, MOPP [mechloretamine (nitrogen mustard), Oncovin (vincristine), procarbazine, prednisone] has most clearly demonstrated leukemogenic, either as first-line or salvage (Brusamolino Cornbleet 1985; Cramer Henry-Amar Jacquillat Santoro Toland Valagussa 1986). A significant increase in leukemic many agents, nitrogen mustard. quantitative study alkylators given HD patients recently published, demonstrating for first time a direct dose-response relation leukemogenesis (Pedersen-Bjergaard Van der Velden 1988). Similar findings were observed other tumor series (Boice Cuzick Greene Haas 1987b). The respective leukemogenicity used current analyzed (Van